Cell competition has recently emerged as an important tumor suppressor mechanism in the thymus that inhibits autonomous thymic maintenance. Here, we show that the oncogenic transcription factor Lmo2 causes autonomous thymic maintenance in transgenic mice by inhibiting early T cell differentiation. This autonomous thymic maintenance results in the development of self-renewing preleukemic stem cells (pre-LSCs) and subsequent leukemogenesis, both of which are profoundly inhibited by restoration of thymic competition or expression of the antiapoptotic factor BCL2. Genomic analyses revealed the presence of Notch1 mutations in pre-LSCs before subsequent loss of tumor suppressors promotes the transition to overt leukemogenesis. These studies demonstrate a critical role for impaired cell competition in the development of pre-LSCs in a transgenic mouse model of T cell acute lymphoblastic leukemia (T-ALL), implying that this process plays a role in the ontogeny of human T-ALL.
Overexpression of Lmo2 initiates T-lymphoblastic leukemia via impaired thymocyte competition
Disclosures: The Walter and Eliza Hall Institute receives milestone and royalty payments related to Venetoclax, and employees may also be eligible for benefits related to these payments. W.S. Alexander and I.J. Majewski reported receiving payments from the Walter and Eliza Hall Institute related to Venetoclax. M.P. McCormack is an employee of iCamuno Biotherapeutics and has served as a consultant for AstraZeneca. D.H.D. Gray reported “other” from Walter and Eliza Hall Institute and grants from Servier outside the submitted work. X. Liu is co-founder of iCamuno Biotherapeutics. No other disclosures were reported.
- Award Id(s): 1003391,1187367,1104145,1113577,1154970,1158024,1058344
Hesham D. Abdulla, Raed Alserihi, Christoffer Flensburg, Waruni Abeysekera, Meng-Xiao Luo, Daniel H.D. Gray, Xiaodong Liu, Gordon K. Smyth, Warren S. Alexander, Ian J. Majewski, Matthew P. McCormack; Overexpression of Lmo2 initiates T-lymphoblastic leukemia via impaired thymocyte competition. J Exp Med 5 June 2023; 220 (6): e20212383. doi: https://doi.org/10.1084/jem.20212383
Download citation file:
Sign in
Client Account
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement